• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MNAM ML375的持续优化:VU6008667的发现,一种具有高中枢神经系统渗透性且在大鼠体内具有适合成瘾研究的短半衰期的MNAM。

Continued optimization of the M NAM ML375: Discovery of VU6008667, an M NAM with high CNS penetration and a desired short half-life in rat for addiction studies.

作者信息

McGowan Kevin M, Nance Kellie D, Cho Hykeyung P, Bridges Thomas M, Conn P Jeffrey, Jones Carrie K, Lindsley Craig W

机构信息

Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, TN 37232, USA; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, TN 37232, USA; Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA.

出版信息

Bioorg Med Chem Lett. 2017 Mar 15;27(6):1356-1359. doi: 10.1016/j.bmcl.2017.02.020. Epub 2017 Feb 13.

DOI:10.1016/j.bmcl.2017.02.020
PMID:28237763
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5508536/
Abstract

This letter describes the continued optimization of M NAM ML375 (VU0483253). While a valuable in vivo tool compound, ML375has an excessively long elimination half-life in rat (t=80h), which can be problematic in certain rodent addiction paradigms (e.g., reinstatement). Thus, we required an M NAM of comparable potency to ML375, but with a rat t of less than 4h. Steep SAR plagued this chemotype, and here we detail aniline replacements that offered some improvements over ML375, but failed to advance. Ultimately, incorporation of a single methyl group to the 9b-phenyl ring acted as a metabolic shunt, providing (S)-11 (VU6008667), an equipotent M NAM, with high CNS penetration, excellent selectivity versus M and the desired short half-life (t=2.3h) in rat.

摘要

这封信描述了M NAM ML375(VU0483253)的持续优化。虽然ML375是一种有价值的体内工具化合物,但它在大鼠体内的消除半衰期过长(t = 80小时),这在某些啮齿动物成瘾模型(如复吸)中可能会出现问题。因此,我们需要一种与ML375效力相当,但大鼠半衰期小于4小时的M NAM。该化学类型存在陡峭的构效关系,在此我们详细介绍了苯胺替代物,它们比ML375有一些改进,但未能取得进展。最终,在9b-苯环上引入一个甲基起到了代谢分流的作用,得到了(S)-11(VU6008667),一种效力相当的M NAM,具有高脑渗透性,对M有优异的选择性,且在大鼠体内具有所需的短半衰期(t = 2.3小时)。

相似文献

1
Continued optimization of the M NAM ML375: Discovery of VU6008667, an M NAM with high CNS penetration and a desired short half-life in rat for addiction studies.MNAM ML375的持续优化:VU6008667的发现,一种具有高中枢神经系统渗透性且在大鼠体内具有适合成瘾研究的短半衰期的MNAM。
Bioorg Med Chem Lett. 2017 Mar 15;27(6):1356-1359. doi: 10.1016/j.bmcl.2017.02.020. Epub 2017 Feb 13.
2
Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges.M5 NAM MLPCN 探针 ML375 的进一步优化:策略与挑战
Bioorg Med Chem Lett. 2015 Feb 1;25(3):690-4. doi: 10.1016/j.bmcl.2014.11.082. Epub 2014 Dec 13.
3
Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375).发现首例 M5 选择性和中枢神经系统穿透性毒蕈碱乙酰胆碱受体负变构调节剂 (NAM):(S)-9b-(4-氯苯基)-1-(3,4-二氟苯甲酰基)-2,3-二氢-1H-咪唑并[2,1-a]异吲哚-5(9bH)-酮 (ML375)。
J Med Chem. 2013 Nov 27;56(22):9351-5. doi: 10.1021/jm4013246. Epub 2013 Nov 13.
4
Selective M muscarinic acetylcholine receptor negative allosteric modulator VU6008667 blocks acquisition of opioid self-administration.选择性 M 毒蕈碱型乙酰胆碱受体负变构调节剂 VU6008667 阻断阿片类药物自我给药的获得。
Neuropharmacology. 2023 Apr 1;227:109424. doi: 10.1016/j.neuropharm.2023.109424. Epub 2023 Jan 28.
5
Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe.高选择性毒蕈碱型乙酰胆碱受体(mAChR)的M5正构拮抗剂VU0488130(ML381)的发现、合成及表征:一种新型分子探针
ChemMedChem. 2014 Aug;9(8):1677-82. doi: 10.1002/cmdc.201402051. Epub 2014 Apr 1.
6
Acute Negative Allosteric Modulation of M Muscarinic Acetylcholine Receptors Inhibits Oxycodone Self-Administration and Cue-Induced Reactivity with No Effect on Antinociception.M 型乙酰胆碱受体的急性负变构调节抑制羟考酮的自我给药和线索诱导反应,而对镇痛无影响。
ACS Chem Neurosci. 2019 Aug 21;10(8):3740-3750. doi: 10.1021/acschemneuro.9b00274. Epub 2019 Jul 24.
7
Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes.基于配体的虚拟筛选以发现新型M5抑制剂化学类型。
Bioorg Med Chem Lett. 2016 Sep 15;26(18):4487-4491. doi: 10.1016/j.bmcl.2016.07.071. Epub 2016 Jul 30.
8
Development of the First Potent, Selective and CNS penetrant M5 Negative Allosteric Modulator (NAM)首个强效、选择性且可穿透中枢神经系统的M5负变构调节剂(NAM)的研发
9
Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins.首个高度偏好M5的毒蕈碱型乙酰胆碱受体配体的发现,一种源自一系列5-三氟甲氧基N-苄基异吲哚酮的M5正变构调节剂。
J Med Chem. 2009 Jun 11;52(11):3445-8. doi: 10.1021/jm900286j.
10
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380).一种强效新型M5正变构调节剂(PAM)的研发,该调节剂具有中枢神经系统暴露活性:1-((1H-吲唑-5-基)磺酰基)-N-乙基-N-(2-(三氟甲基)苄基)哌啶-4-甲酰胺(ML380)。
J Med Chem. 2014 Sep 25;57(18):7804-10. doi: 10.1021/jm500995y. Epub 2014 Sep 3.

引用本文的文献

1
A New Era of Muscarinic Acetylcholine Receptor Modulators in Neurological Diseases, Cancer and Drug Abuse.毒蕈碱型乙酰胆碱受体调节剂在神经疾病、癌症和药物滥用领域的新时代。
Pharmaceuticals (Basel). 2025 Mar 5;18(3):369. doi: 10.3390/ph18030369.
2
A golden age of muscarinic acetylcholine receptor modulation in neurological diseases.神经退行性疾病中毒蕈碱型乙酰胆碱受体调节的黄金时代。
Nat Rev Drug Discov. 2024 Oct;23(10):743-758. doi: 10.1038/s41573-024-01007-1. Epub 2024 Aug 14.
3
Discovery of a potent M antagonist with improved clearance profile. Part 2: Pyrrolidine amide-based antagonists.发现一种具有改善清除特性的强效 M 拮抗剂。第 2 部分:基于吡咯烷酰胺的拮抗剂。
Bioorg Med Chem Lett. 2022 Dec 15;78:129021. doi: 10.1016/j.bmcl.2022.129021. Epub 2022 Oct 10.
4
Unified Approach to Diverse Fused Fragments via Catalytic Dehydrative Cyclization.通过催化脱水环化实现多种融合片段的统一方法。
Chemistry. 2022 Aug 26;28(48):e202201107. doi: 10.1002/chem.202201107. Epub 2022 Jul 4.
5
Targeting muscarinic receptors to treat schizophrenia.针对毒蕈碱受体治疗精神分裂症。
Behav Brain Res. 2021 May 7;405:113201. doi: 10.1016/j.bbr.2021.113201. Epub 2021 Feb 26.
6
Examining the role of muscarinic M5 receptors in VTA cholinergic modulation of depressive-like and anxiety-related behaviors in rats.探讨 VTA 胆碱能系统中毒蕈碱 M5 受体在大鼠抑郁和焦虑样行为中的作用。
Neuropharmacology. 2020 Jul;171:108089. doi: 10.1016/j.neuropharm.2020.108089. Epub 2020 Apr 5.
7
Discovery and Optimization of Potent and CNS Penetrant M-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold.新型手性 N-(茚满基)哌啶酰胺骨架衍生的强效、可穿透血脑屏障的 M 型优先正变构调节剂的发现与优化。
ACS Chem Neurosci. 2018 Jul 18;9(7):1572-1581. doi: 10.1021/acschemneuro.8b00126. Epub 2018 Apr 26.
8
Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists.新型可穿透中枢神经系统的泛毒蕈碱拮抗剂3-(4-芳基/杂芳基磺酰基)哌嗪-1-基)-6-(哌啶-1-基)哒嗪的发现与优化
Bioorg Med Chem Lett. 2017 Aug 1;27(15):3576-3581. doi: 10.1016/j.bmcl.2017.05.042. Epub 2017 May 15.
9
Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype.作为具有新型化学结构类型的中枢神经系统渗透型泛毒蕈碱拮抗剂的4,6-二取代嘧啶的合成与评价
Bioorg Med Chem Lett. 2017 Jun 1;27(11):2479-2483. doi: 10.1016/j.bmcl.2017.04.009. Epub 2017 Apr 4.

本文引用的文献

1
Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes.基于配体的虚拟筛选以发现新型M5抑制剂化学类型。
Bioorg Med Chem Lett. 2016 Sep 15;26(18):4487-4491. doi: 10.1016/j.bmcl.2016.07.071. Epub 2016 Jul 30.
2
Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.GPCR变构调节剂发现中的实用策略与概念:代谢型谷氨酸受体的最新进展
Chem Rev. 2016 Jun 8;116(11):6707-41. doi: 10.1021/acs.chemrev.5b00656. Epub 2016 Feb 16.
3
Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges.M5 NAM MLPCN 探针 ML375 的进一步优化:策略与挑战
Bioorg Med Chem Lett. 2015 Feb 1;25(3):690-4. doi: 10.1016/j.bmcl.2014.11.082. Epub 2014 Dec 13.
4
Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.发现用于治疗中枢神经系统疾病的GPCR变构调节剂的机遇与挑战。
Nat Rev Drug Discov. 2014 Sep;13(9):692-708. doi: 10.1038/nrd4308.
5
Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380).一种强效新型M5正变构调节剂(PAM)的研发,该调节剂具有中枢神经系统暴露活性:1-((1H-吲唑-5-基)磺酰基)-N-乙基-N-(2-(三氟甲基)苄基)哌啶-4-甲酰胺(ML380)。
J Med Chem. 2014 Sep 25;57(18):7804-10. doi: 10.1021/jm500995y. Epub 2014 Sep 3.
6
Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe.高选择性毒蕈碱型乙酰胆碱受体(mAChR)的M5正构拮抗剂VU0488130(ML381)的发现、合成及表征:一种新型分子探针
ChemMedChem. 2014 Aug;9(8):1677-82. doi: 10.1002/cmdc.201402051. Epub 2014 Apr 1.
7
Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.七跨膜受体的变构调节:理论、实践及中枢神经系统药物发现的机遇
J Med Chem. 2012 Feb 23;55(4):1445-64. doi: 10.1021/jm201139r. Epub 2012 Jan 6.
8
Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice.毒蕈碱型M5乙酰胆碱受体缺陷小鼠中可卡因自我给药行为减少。
J Neurosci. 2005 Sep 7;25(36):8141-9. doi: 10.1523/JNEUROSCI.2077-05.2005.
9
Role for M5 muscarinic acetylcholine receptors in cocaine addiction.M5毒蕈碱型乙酰胆碱受体在可卡因成瘾中的作用。
J Neurosci Res. 2003 Oct 1;74(1):91-6. doi: 10.1002/jnr.10728.
10
Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia.M5毒蕈碱型乙酰胆碱受体的缺失减弱了吗啡强化作用和戒断反应,但不影响吗啡镇痛作用。
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11452-7. doi: 10.1073/pnas.162371899. Epub 2002 Aug 1.